Sanders Morris Harris LLC Buys Shares of 24,500 Xenon Pharmaceuticals Inc (NASDAQ:XENE)

Sanders Morris Harris LLC purchased a new position in shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 24,500 shares of the biopharmaceutical company’s stock, valued at approximately $288,000.

Other large investors have also recently added to or reduced their stakes in the company. Two Sigma Advisers LP increased its stake in shares of Xenon Pharmaceuticals by 58.9% in the 2nd quarter. Two Sigma Advisers LP now owns 100,900 shares of the biopharmaceutical company’s stock valued at $1,265,000 after buying an additional 37,400 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in shares of Xenon Pharmaceuticals by 173.8% in the 2nd quarter. Schonfeld Strategic Advisors LLC now owns 35,600 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 22,600 shares during the period. FMR LLC grew its stake in shares of Xenon Pharmaceuticals by 38.5% in the 2nd quarter. FMR LLC now owns 2,199,054 shares of the biopharmaceutical company’s stock valued at $27,576,000 after buying an additional 611,518 shares during the period. Great West Life Assurance Co. Can acquired a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $30,000. Finally, Orbimed Advisors LLC grew its stake in shares of Xenon Pharmaceuticals by 50.2% in the 2nd quarter. Orbimed Advisors LLC now owns 2,497,917 shares of the biopharmaceutical company’s stock valued at $31,324,000 after buying an additional 835,105 shares during the period. 79.90% of the stock is owned by institutional investors and hedge funds.

Shares of Xenon Pharmaceuticals stock traded up $0.34 during mid-day trading on Friday, hitting $11.28. 62,848 shares of the stock were exchanged, compared to its average volume of 206,670. Xenon Pharmaceuticals Inc has a 12 month low of $7.00 and a 12 month high of $18.45. The company has a 50-day simple moving average of $11.36 and a 200 day simple moving average of $12.15. The company has a market capitalization of $394.74 million, a P/E ratio of -11.63 and a beta of 1.22.

Several analysts have recently commented on the company. BidaskClub downgraded Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 4th. SVB Leerink began coverage on shares of Xenon Pharmaceuticals in a research report on Friday, October 2nd. They issued an “outperform” rating and a $22.00 price target on the stock. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 14th. ValuEngine raised shares of Xenon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, August 3rd. Finally, Bloom Burton reaffirmed a “buy” rating and issued a $25.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $21.50.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Featured Article: Marijuana Stocks

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.